# A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)

> **NCT07557446** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Angitia Biopharmaceuticals Guangzhou Limited** · enrollment: 48 (estimated)

## Conditions studied

- Osteogenesis Imperfecta (OI)

## Interventions

- **DRUG:** AGA2115

## Key facts

- **NCT ID:** NCT07557446
- **Lead sponsor:** Angitia Biopharmaceuticals Guangzhou Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-04
- **Final completion:** 2029-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07557446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07557446, "A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07557446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*